Covers 739 genes and is guideline-complete
across advanced
solid tumors.1-6*
MSI, microsatellite instability; TMB, tumor mutation burden.
*Guardant360 is guideline-complete for genomic biomarkers.
†Includes TERT promoter region.
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Product availability may vary depending on region.